BackDrugs Made In America Acquisition II Ordinary Shares Overview

Drugs Made In America Acquisition II Ordinary Shares Receivables

Drugs Made In America Acquisition II Ordinary Shares's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-2596.00 vs prior year quarter

Peer trimmed avg / median

Loading

Drugs Made In America Acquisition II Ordinary Shares Receivables History

Loading

Drugs Made In America Acquisition II Ordinary Shares vs. peers: Receivables Comparison

Loading

Drugs Made In America Acquisition II Ordinary Shares Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Drugs Made In America Acquisition II Ordinary Shares (DMII) FAQ

As of the most recent data (June 2026), DMII shows a receivables of $0. That compares with $2.6K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DMII's receivables is now $0 (was $2.6K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Drugs Made In America Acquisition II Ordinary Shares is outperforming or lagging.

Tracking DMII's receivables over time shows whether Drugs Made In America Acquisition II Ordinary Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $2.6K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Drugs Made In America Acquisition II Ordinary Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.